Fangchinoline inhibits growth and biofilm of Candida albicans by inducing <scp>ROS</scp> overproduction

Longfei Yang, Xiaonan Wang, Zhiming Ma, Yujie Sui, Xin LiuJournal of Cellular and Molecular Medicine 2024 · DOI

TL;DR

This study investigates fangchinoline, a natural compound from Chinese herbs, as a potential antifungal agent against Candida albicans. The research demonstrates that fangchinoline effectively inhibits C. albicans growth and biofilm formation by inducing excessive reactive oxygen species (ROS) production and damaging cell membranes. Its synergistic effects with existing antifungal drugs suggest a promising avenue for developing new therapies against drug-resistant fungal infections.

What Problem Does This Paper Address?

Candida albicans is a major cause of opportunistic fungal infections, particularly in immunocompromised individuals, leading to significant public health and economic burdens. The rise of antifungal drug resistance and a shortage of effective treatments necessitate the discovery of novel antifungal agents. Natural products have emerged as a promising source for such discoveries. While some natural compounds have shown potential, their efficacy against the complex virulence factors of C. albicans, such as its ability to form biofilms, remains a critical area of research. Biofilms, in particular, are notoriously difficult to eradicate due to their protective extracellular matrix and increased tolerance to antifungals. This paper addresses the need for new antifungal strategies by exploring the potential of fangchinoline, a bis-benzylisoquinoline alkaloid, against C. albicans, focusing on its effects on both planktonic growth and key virulence factors like biofilm formation.

Methods

The researchers employed a multi-pronged approach to evaluate fangchinoline's antifungal activity:

  • Antifungal Susceptibility Testing: Standard broth microdilution assays (following CLSI guidelines) were used to determine the Minimum Inhibitory Concentration (MIC) and Minimum Fungicidal Concentration (MFC) of fangchinoline against various Candida species.
  • Virulence Factor Assays:
    • Adhesion: MTT and XTT reduction assays, along with Calcofluor White (CFW) staining and microscopy, were used to assess fangchinoline's impact on the adhesion of C. albicans to polystyrene surfaces.
  • Hyphal Growth: Microscopic observation was used to evaluate fangchinoline's effect on hyphal formation, a key virulence factor.
  • Biofilm Formation and Development: XTT reduction assays and Confocal Laser Scanning Microscopy (CLSM) were employed to assess fangchinoline's ability to inhibit both the formation and development of C. albicans biofilms.
  • EPS Production: A colorimetric assay was used to measure the effect of fangchinoline on the production of extracellular polymeric substances (EPS) in preformed biofilms.
  • Mechanism of Action Studies:
    • Cell Membrane Permeability: Propidium Iodide (PI) staining followed by CLSM was used to detect cell membrane damage.
  • ROS Production: DCFH-DA staining and CLSM were used to visualize and quantify intracellular reactive oxygen species (ROS) production.
  • NAC Rescue Test: N-acetyl-cysteine (NAC), a known ROS scavenger, was used to confirm the role of ROS in fangchinoline's antifungal activity.
  • Drug Combination Testing: A checkerboard assay was performed to evaluate the synergistic interactions between fangchinoline and established antifungal drugs (amphotericin B, fluconazole, and caspofungin) using the Fractional Inhibitory Concentration Index (FICI).

Datasets

Not discussed in the paper. The study primarily uses laboratory strains of Candida albicans (SC5314 and ATCC10231) and other Candida species obtained from culture collections.

Key Insights and Ideas

  • Natural Product Potential: Fangchinoline, a compound derived from a traditional Chinese herb, demonstrates significant antifungal activity, highlighting the continued value of natural products in drug discovery.
  • Targeting Virulence Factors: Beyond simply killing planktonic cells, fangchinoline effectively targets key virulence mechanisms of C. albicans, including adhesion and hyphal growth, which are crucial for infection establishment.
  • Biofilm Disruption: The compound shows promise in combating biofilms, a major challenge in treating Candida infections, by inhibiting both their formation and development.
  • ROS as a Key Mediator: The study strongly implicates ROS overproduction as a primary mechanism by which fangchinoline exerts its antifungal and anti-biofilm effects, a finding supported by the NAC rescue experiments.
  • Synergistic Potential: Fangchinoline's ability to synergize with existing antifungal drugs is a critical finding, suggesting it could be used to enhance the efficacy of current treatments and potentially overcome resistance.

Key Results

  • Fangchinoline exhibited antifungal activity against all tested Candida species, with MIC values no higher than 50 µg/mL for C. albicans.
  • It significantly inhibited C. albicans adhesion to polystyrene surfaces in a dose-dependent manner (up to 70% inhibition at 100 µg/mL).
  • Fangchinoline suppressed hyphal growth, with higher concentrations leading to a yeast morphology.
  • The compound demonstrated potent anti-biofilm activity, reducing biofilm viability by up to 82% at 200 µg/mL and inhibiting biofilm development.
  • Fangchinoline treatment led to increased cell membrane permeability and induced significant intracellular ROS overproduction in C. albicans.
  • The addition of NAC partially rescued the viability of biofilms treated with fangchinoline and increased the MIC of fangchinoline, confirming the role of ROS.
  • Fangchinoline showed synergistic interactions with amphotericin B, fluconazole, and caspofungin, with FICI values below 0.5.

Limitations and Future Work

  • Concentration: The authors acknowledge that the concentrations of fangchinoline used in some experiments were higher compared to other antifungal agents, suggesting a need for optimization of its chemical structure.
  • Mechanism Specificity: While ROS and cell membrane damage are implicated, the precise molecular interactions and the direct cause-and-effect relationship between ROS and membrane damage require further exploration.
  • In Vivo Studies: The study was conducted in vitro. Future work should focus on evaluating the efficacy and safety of fangchinoline in animal models of Candida infections.
  • Structure-Activity Relationship: Given the existence of natural analogues and the maturity of synthetic methods for bis-benzylisoquinoline alkaloids, exploring structure-activity relationships could lead to more potent and optimized derivatives.
  • Inflammation Modulation: The paper notes fangchinoline's known anti-inflammatory properties and suggests it might act through dual mechanisms (antifungal and anti-inflammatory) in treating C. albicans-associated inflammatory diseases, which warrants further investigation.

Summary updated

Abstract

Infections caused by Candida species, especially Candida albicans, threaten the public health and create economic burden. Shortage of antifungals and emergence of drug resistance call for new antifungal therapies while natural products were attractive sources for developing new drugs. In our study, fangchinoline, a bis-benzylisoquinoline alkaloid from Chinese herb Stephania tetrandra S. Moore, exerted antifungal effects on planktonic growth of several Candida species including C. albicans, with MIC no more than 50 μg/mL. In addition, results from microscopic, MTT and XTT reduction assays showed that fangchinoline had inhibitory activities against the multiple virulence factors of C. albicans, such as adhesion, hyphal growth and biofilm formation. Furthermore, this compound could also suppress the metabolic activity of preformed C. albicans biofilms. PI staining, followed by confocal laser scanning microscope (CLSM) analysis showed that fangchinoline can elevate permeability of cell membrane. DCFH-DA staining suggested its anti-Candida mechanism also involved overproduction of intracellular ROS, which was further confirmed by N-acetyl-cysteine rescue tests. Moreover, fangchinoline showed synergy with three antifungal drugs (amphotericin B, fluconazole and caspofungin), further indicating its potential use in treating C. albicans infections. Therefore, these results indicated that fangchinoline could be a potential candidate for developing anti-Candida therapies.
BibTeX
@article{yang2024fangchinoline,
  author = {Longfei Yang and Xiaonan Wang and Zhiming Ma and Yujie Sui and Xin Liu},
  title = {{Fangchinoline inhibits growth and biofilm of <i>Candida albicans</i> by inducing <scp>ROS</scp> overproduction}},
  journal = {Journal of Cellular and Molecular Medicine},
  year = {2024},
  doi = {10.1111/jcmm.18354},
}
Figure